ZHOU FANGJIAN
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma (NCT05738694) | ZHOU FANGJIAN | 2023-04-19 |
Track ZHOU FANGJIAN automatically
Every clearance here is in the API, with alerts when new ones post.